Fig. 3.

Compound 4 (A) and cromolyn 1 (B) block S100P binding to RAGE in a dose dependent manner. Human S100P (2 μM) coated wells were incubated with increasing concentrations of the compound tested, and exposed to human RAGE-Fc (100 nM) followed by goat anti-human secondary antibody to detect RAGE bound S100P. Data are compared to S100P/RAGE binding with no inhibitor (untreated, 100%) and 0.001% DMSO control (DMSO) and are presented as mean ± SEM; data is significant by one way ANOVA, where ∗∗ = p < 0.01 and ∗∗∗ = p < 0.001; significance by Dunnett’s Multiple comparison post-hoc test is expressed as f = p < 0.05, ff = p < 0.01 and fff = p < 0.001 compared to vehicle control (0.001% DMSO); n = 12 from 4 plates.